胆道恶性肿瘤辅助治疗的研究现状及展望

doi:10.11904/j.issn.1002-3070.2022.02.010

摘要/Abstract

摘要： 胆道恶性肿瘤侵袭性强,恶性程度高,预后差。早期根治性切除是目前首选的治疗方法,也是唯一可能获得长期生存的方法。但大多数患者初诊时已为晚期,只有约20%的患者有手术机会。不仅如此,即使行根治性手术,复发率依然极高。为了降低术后复发率,多年来人们一直致力于探索辅助治疗策略,包括放疗、化疗和放化疗结合。但大多数数据来源于Ⅱ期临床试验和回顾性研究,缺乏高质量的数据来证实辅助治疗的效果。近年来随着几项大型随机临床试验的发布以及精准治疗的发展,越来越多的研究聚焦于该领域,结果令人期待。本综述总结并分析了近年来胆道恶性肿瘤辅助治疗领域的研究数据,并探讨了未来的研究方向。

关键词: 胆道恶性肿瘤, 辅助治疗, 放化疗, 靶向治疗, 免疫治疗

Abstract: Biliary tract malignant tumors are aggressive,high malignant and have a poor prognosis.Early radical resection is currently the preferred treatment method and the only possible long-term survival method.However,most patients are already at an advanced stage when they are diagnosed,and only about 20% of the patients have the chance of surgery.Not only that,even if radical surgery is performed,the recurrence rate is still extremely high.In order to reduce the postoperative recurrence rate,people have been committed to exploring adjuvant treatment strategies for many years,including radiotherapy,chemotherapy and combination of radiotherapy and chemotherapy.However,most of the data come from phase II clinical trials and retrospective studies,and there is a lack of high-quality data to confirm the effects of adjuvant therapy.In recent years,with the release of several large randomized clinical trials and the development of precision treatments,more and more studies have focused on this field,and the results are promising.This review summarizes and analyzes recent research data in the field of adjuvant treatment of biliary malignant tumors,and discusses future research directions.

Key words: Biliary malignant tumors, Adjuvant therapy, Radiotherapy and chemotherapy, Targeted therapy, Immunotherapy

中图分类号:

R735.8

吴芳芳, 郑桐森. 胆道恶性肿瘤辅助治疗的研究现状及展望[J]. 实用肿瘤学杂志, 2022, 36(2): 156-161.

WU Fangfang, ZHENG Tongsen. Research status and prospect of adjuvant therapy for biliary tract malignant tumors[J]. Journal of Practical Oncology, 2022, 36(2): 156-161.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2022.02.010

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2022/V36/I2/156

参考文献

1 Sutherland M,Ahmed O,Zaidi A,et al.Current progress in systemic therapy for biliary tract cancers[J].J Hepatobiliary Pancreat Sci,2021,10:1002.
2 Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(2):394-424.
3 Banales JM,Cardinale V,Carpino G,et al.Expert consensus document:Cholangiocarcinoma:current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma(ENS-CCA)[J].Nat Rev Gastroenterol Hepatol,2016,13:261-280.
4 Lamarca A,EdelinE J,Mcnamara MG,et al.Current standards and future perspectives in adjuvant treatment for biliary tract cancers[J].Cancer Treat Rev,2020,84:101936.
5 Kim BH,Kim E,Kim K,et al.The impact of perioperative CA19-9 change on the survival and recurrence patterns after adjuvant chemoradiotherapy in resectable extrahepatic cholangiocarcinoma[J].J Surg Oncol,2018,117:380-388.
6 Groot Koerkamp B,Wiggers JK,Gonen M,et al.Survival after resection of perihilar cholangiocarcinoma-development and external validation of a prognostic nomogram[J].Ann Oncol,2016,27(4):753.
7 Horgan AM,Amir E,Walter T,et al.Adjuvant therapy in the treatment of biliary tract cancer:a systematic review and meta-analysis[J].J Clin Oncol,2012,30(16):1934-1940.
8 Ghidini M,Tomasello G,Botticelli A,et al.Adjuvant chemotherapy for resected biliary tract cancers:a systematic review and meta-analysis[J].HPB(Oxford),2017,19(9):741-748.
9 Wang L,Deng M,Ke Q,et al.Postoperative adjuvant therapy following radical resection for intrahepatic cholangiocarcinoma:a multicenter retrospective study[J].Cancer Med,2020,9(8):2674-2685.
10 Altman AM,Kizy S,Marmor S,et al.Adjuvant chemotherapy for intrahepatic cholangiocarcinoma:approaching clinical practice consensus?[J].Hepatobiliary Surg Nutr,2020,9(5):577-586.
11 Cloyd JM,Pawlik TM.Trends in the use of adjuvant therapy for resected intrahepatic cholangiocarcinoma:getting ahead of the data[J].Hepatobiliary Surg Nutr,2021,10(4):515-517.
12 Woo SM,Yoon KA,Hong EK,et al.DCK expression,a potential predictive biomarker in the adjuvant gemcitabine chemotherapy for biliary tract cancer after surgical resection:results from a phase II study[J].Oncotarget,2017,8(46):81394-81404.
13 Kainuma O,Miura F,Furukawa D,et al.Feasibility and efficacy of gemcitabine plus cisplatin combination therapy after curative resection for biliary tract cancer[J].J Hepatobiliary Pancreat Sci,2015,22(11):789-794.
14 Siebenhüner AR,Seifert H,Bachmann H,et al.Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine:A prospective single center phase II study[J].BMC Cancer,2018,18(1):72.
15 Ebata T,Hirano S,Konishi M,et al.Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer[J].Br J Surg,2018,105(3):192-202.
16 Edeline J,Benabdelghani M,Bertaut A,et al.Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer(PRODIGE 12-ACCORD 18-UNICANCER GI):a randomized phase III study[J].J Clin Oncol,2019,37:658-667.
17 Kim KP,Jang G,Hong YS,et al.Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer:influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity[J].Br J Cancer,2011,104(4):605-612.
18 Yoo C,Han B,Kim HS.et al.Multicenter phase II study of oxaliplatin,irinotecan,and S-1 as first-line treatment for patients with recurrent or metastatic biliary tract cancer[J].Cancer Res Treat,2018,50(4):1324-1330.
19 Obayashi S,Nagano H,Tomokuni A,et al.A prospective,randomized phase II study of adjuvant gemcitabine versus S-1 after major hepatectomy for biliary tract cancer(KHBO 1208):Kansai Hepato-Biliary Oncology Group[J].Ann Surg,2019,270(2):230-237.
20 Seita K,Ebata T,Mizuno T,et al.Phase 2 trial of adjuvant chemotherapy with S-1 for node-positive biliary tract cancer(N-SOG 09)[J].Ann Surg Oncol,2020,27(7):2348-2356.
21 Nakachi K,Konishi M,Ikeda M,et al.A randomized phase III trial of adjuvant S-1 therapy vs.observation alone in resected biliary tract cancer:Japan Clinical Oncology Group Study(JCOG1202,ASCOT)[J].Jpn J Clin Oncol,2018,48(4):392-395.
22 Song S,Yang W,Tian H,et al.The efficacy and safety of 5-fluorouracil based adjuvant therapy in resected biliary tract cancer:a systematic review and meta-analysis[J].Clin Res Hepatol Gastroenterol,2022,46(2):101788.
23 Primrose JN,Fox RP,Palmer DH,et al.Capecitabine compared with observation in resected biliary tract cancer(BILCAP):a randomised,controlled,multicentre,phase 3 study[J].Lancet Oncol,2019,20:663-673.
24 Chen X,Meng F,Xiong H,et al.Adjuvant therapy for resectable biliary tract cancer:a bayesian network analysis[J].Front Oncol,2021,11:600027.
25 Takahashi D,Mizuno T,Yokoyama Y,et al.Adjuvant S-1 vs gemcitabine for node-positive perihilar cholangiocarcinoma:a propensity score-adjusted analysis[J].J Hepatobiliary Pancreat Sci,2021,28(9):716-726.
26 Stein A,Arnold D,Bridgewater J,et al.Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma(ACTICCA-1 trial)-a randomized,multidisciplinary,multinational phase III trial[J].BMC Cancer,2015,15:564.
27 Hyder O,Dodson RM,Sachs T,et al.Impact of adjuvant external beam radiotherapy on survival in surgically resected gallbladder adenocarcinoma:a propensity score-matched Surveillance,Epidemiology,and End Results analysis[J].Surgery,2014,155(1):85-93.
28 Leng KM,Liu YP,Wang ZD,et al.Results of adjuvant radiation therapy for locoregional perihilar cholangiocarcinoma after curative intent resection[J].Onco Targets Ther,2017,10:2257-2266.
29 Ren B,Guo Q,Yang Y,et al.A meta-analysis of the efficacy of postoperative adjuvant radiotherapy versus no radiotherapy for extrahepatic cholangiocarcinoma and gallbladder carcinoma[J].Radiat Oncol,2020,15(1):15.
30 Ben-Josef E,Guthrie KA,El-Khoueiry AB,et al.SWOG S0809:A phase ii intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma[J].J Clin Oncol,2015,33:2617-2622.
31 Shroff RT,Kennedy EB,Bachini M,et al.Adjuvant therapy for resected biliary tract cancer:ASCO clinical practice guideline[J].J Clin Oncol,2019,37(12):1015-1027.
32 Kobayashi S,Gotoh K,Takahashi H,et al.Clinicopathological features of surgically-resected biliary tract cancer following chemo-radiation therapy[J].Anticancer Res,2016,36(1):335-342.
33 Le Roy B,Gelli M,Pittau G,et al.Neoadjuvant chemotherapy for initially unresectable intrahepatic cholangiocarcinoma[J].Br J Surg,2018,105(7):839-847.
34 Sumiyoshi T,Shima Y,Okabayashi T,et al.Chemoradiotherapy for initially unresectable locally advanced cholangiocarcinoma[J].World J Surg,2018,42(9):2910-2918.
35 Goetze TO,Bechstein WO,Bankstahl US,et al.Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone with or without adjuvant chemotherapy in incidentally detected gallbladder carcinoma after simple cholecystectomy or in front of radical resection of BTC(ICC/ECC)-a phase III study of the German registry of incidental gallbladder carcinoma platform(GR)-the AIO/CALGP/ACO-GAIN-trial[J].BMC Cancer,2020,20(1):122.
36 JCOG1920:A phase III trial of neoadjuvant Gemcitabine + Cisplatin + S-1(GCS)vs.surgery first for resectable biliary tract cancer(NABICA T).https://jrct.niph.go.jp/en-latest-detail/jRCTs031200388.
37 Lin J,Cao Y,Yang X,et al.Mutational spectrum and precision oncology for biliary tract carcinoma[J].Theranostics,2021,11(10):4585-4598.
38 Yoo C,Shin SH,Park JO,et al.Current status and future perspectives of perioperative therapy for resectable biliary tract cancer:a multidisciplinary review[J].Cancers(Basel),2021,13(7):1647.

[1]	侯建勋, 王洪斌. 外泌体对乳腺癌诊疗一体化影响的研究进展[J]. 实用肿瘤学杂志, 2022, 36(2): 178-182.
[2]	易小琦, 邓红彬. PD-1/PD-L1抑制剂在膀胱癌新辅助治疗中的应用进展[J]. 实用肿瘤学杂志, 2022, 36(2): 183-187.
[3]	唐菊, 尚利华. BMI与免疫检查点抑制剂治疗恶性肿瘤疗效的关系[J]. 实用肿瘤学杂志, 2022, 36(2): 188-192.
[4]	张文静, 刘金爽, 王丹, 黎清炜, 李志伟. 胰腺癌新辅助治疗的研究现状[J]. 实用肿瘤学杂志, 2022, 36(1): 64-68.
[5]	杨开炎, 韦永昌, 杨秋云, 唐凤珠. 鼻咽癌的免疫治疗研究进展[J]. 实用肿瘤学杂志, 2021, 35(6): 542-546.
[6]	李响, 胡洋, 张清媛. 肿瘤突变负荷作为乳腺癌免疫治疗的新兴生物标志物的研究进展[J]. 实用肿瘤学杂志, 2021, 35(6): 568-571.
[7]	马补换, 刘彩霞. Jagged1促进乳腺癌发生发展及远处转移的研究进展[J]. 实用肿瘤学杂志, 2021, 35(5): 452-457.
[8]	刘文, 乔文波. 程序性死亡蛋白1及其配体在结直肠癌中的临床研究现状[J]. 实用肿瘤学杂志, 2021, 35(4): 370-375.
[9]	马明瑞, 连洁, 刘超, 娄长杰, 张艳桥. 消化系统肿瘤“免疫治疗前移”的探索[J]. 实用肿瘤学杂志, 2021, 35(3): 258-262.
[10]	王萌萌, 连洁, 李恒震, 张艳桥. 胃肠胰神经内分泌肿瘤的免疫治疗研究进展[J]. 实用肿瘤学杂志, 2021, 35(2): 154-159.
[11]	王明明, 陈晓品. 抗PD-1/PD-L1和CTLA-4免疫治疗在头颈鳞癌中的研究进展[J]. 实用肿瘤学杂志, 2021, 35(2): 179-183.
[12]	李瑞阳,方琳(综述),张艳桥(审校). 食管癌免疫治疗研究进展[J]. 实用肿瘤学杂志, 2021, 35(1): 41-45.
[13]	刘学静(综述),徐燕颖(审校). B7-H6在恶性肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2021, 35(1): 46-49.
[14]	张璐,陆静钰(综述),陆海军(审校). 头颈部鳞癌相关生物标志物与免疫治疗预后的关系[J]. 实用肿瘤学杂志, 2021, 35(1): 55-58.
[15]	姚克非,张博淼(综述),崔滨滨(审校). 低位直肠癌选择性侧方淋巴结清扫研究进展[J]. 实用肿瘤学杂志, 2021, 35(1): 69-72.